Drugs / CERTOCICLIB
CERTOCICLIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05252416 | Apr 2022 → Jul 2025 | carcinosarcoma, endometrial cancer, esophageal adenocarcinoma, gastric cancer +2 | Blueprint Medicines Corporation | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-05-23 | Blueprint Medicines Corporation | Results Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting blueprintmedicines.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-05-23 | Blueprint Medicines Corporation | Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting blueprintmedicines.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CERTOCICLIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068424 ↗ |
| Known as | BLU-170298 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068424 ↗ |
| Known as | BLU-222 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05252416 ↗ |
| Known as | CDK2 INHIBITOR BLU-222 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068424 ↗ |
| Action | Inhibit | “BLU-222, a selective inhibitor of CDK2.” NCT05252416 ↗ |
| Modality | Small molecule | — CHEMBL6068424 ↗ |